Why Cognition Therapeutics Stock Is Plunging On Alzheimer's Disease Related News Today
Portfolio Pulse from Vandana Singh
Cognition Therapeutics Inc (NASDAQ:CGTX) announced the results from its Phase 2 study of CT1812 in adults with Alzheimer's disease. The study met its primary endpoints for safety and tolerability, and demonstrated positive effects for CT1812-treated participants. However, the results were not statistically significant, which may be causing investor concern. CGTX shares are down 20.0% at $2.00.
June 28, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cognition Therapeutics' Phase 2 study of CT1812 shows positive effects but not statistically significant, causing a 20% drop in CGTX shares.
The company's stock price is likely to be negatively impacted due to the lack of statistical significance in the study results, despite the positive effects observed. This could be causing investor concern, leading to a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100